Cybin to Present at Upcoming Cantor and Benzinga Investor Conferences

Rhea-AI Summary

Cybin, a biotechnology company focused on psychedelic therapeutics, announced that CEO Doug Drysdale will present at two investor conferences on September 30, 2021. The conferences are the Cantor Virtual Global Healthcare Conference at 2:00 PM ET and the Benzinga Healthcare Small Cap Conference at 12:15 PM ET, followed by a panel discussion on mental health therapies. Both events will be available via live webcast. Cybin is dedicated to advancing psychedelic drug development for psychiatric disorders, employing innovative drug discovery and delivery techniques.

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting virtually at two upcoming investor conferences as follows:

Cantor Virtual Global Healthcare Conference, Fireside Chat:
Date: Thursday, September 30, 2021
Time: 2:00PM ET
Webcast: https://wsw.com/webcast/cantor12/clxpf/2262050

The presentation will be webcast live using the link above, and a replay will be available for 90 days.

Benzinga Healthcare Small Cap Conference, Presentation and Panel Discussion:
Date: Thursday, September 30, 2021
Time: 12:15PM ET
Webcast: https://www.benzinga.com/events/small-cap/healthcare/september-30-track-2/

Immediately following the presentation, Mr. Drysdale will participate on a panel, “Addressing Mental Health through Emerging Therapies,” at 12:35PM ET. Both the presentation and panel discussion will be webcast live using the link above.

About Cybin
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Cautionary Notes and Forward-Looking Statements
Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding enhanced liquidity, the value of additional capital markets exposure, access to institutional and retail investors, the Company’s new strategic brand messaging campaign, and psychedelic drug development programs to potentially treat mental health disorders. There are numerous risks and uncertainties that could cause actual results and Cybin’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.

The NEO Exchange has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005146/en/

Investors:

Tim Regan/Scott Eckstein

KCSA Strategic Communications

Cybin@kcsa.com

Lisa M. Wilson

In-Site Communications, Inc.

lwilson@insitecony.com

Media:

John Kanakis

Cybin Inc.

John@cybin.com

Source: Cybin Inc.

FAQ

When is Cybin presenting at investor conferences?

Cybin will present at two investor conferences on September 30, 2021.

What time is the Cantor Virtual Global Healthcare Conference presentation?

The presentation at the Cantor Virtual Global Healthcare Conference is scheduled for 2:00 PM ET.

Where can I watch Cybin's conference presentations?

Cybin's presentations will be available via live webcast at the respective conference links.

What topics will Cybin cover during the investor conferences?

Cybin will discuss its psychedelic therapeutics and mental health therapies at the conferences.

Who is the CEO of Cybin presenting at the conferences?

Doug Drysdale, the CEO of Cybin, will present at the conferences.